Mark H. Johnson

Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.

The objectives of this review are to describe the basic science underlying the development of Rho kinase inhibitors as a therapy to lower IOP and to summarize the results of the clinical studies reported to date.

Scientific Concerns About Recent Fluid-Structure Interaction Models of the Aqueous Humor Outflow Pathway.

As a result, this body of work draws potentially misleading and erroneous conclusions about aqueous humor dynamics.

Biomechanics of Schlemm's canal endothelium and intraocular pressure reduction.

Significantly, glaucomatous SC cells appear to be hyper-responsive to substrate stiffness. Thus, evidence suggests that targeting the material properties of SC cells will have therapeutic benefits for lowering intraocular pressure in glaucoma.